{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:41:33Z","timestamp":1791405693564,"version":"4.3.3"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.anai.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:25:45Z","timestamp":1752596745000},"page":"403-411.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["ALERT (ChAracterizing uncontroLled sevERe asThma in Canada)"],"prefix":"10.1016","volume":"135","author":[{"given":"Andr\u00e9anne","family":"C\u00f4t\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koyo","family":"Usuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Tusin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu K.G.","family":"Jayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim Tian","family":"Yu Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Waserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2025.07.005_bib0001","unstructured":"Government of Canada. Canadian Chronic Disease Surveillance System (CCDSS). Accessed March 17, 2025. Available at: https:\/\/health-infobase.canada.ca\/ccdss\/data-tool\/Index"},{"key":"10.1016\/j.anai.2025.07.005_bib0002","unstructured":"Asthma Canada. Severe asthma. Accessed March 17, 2025. Available at: https:\/\/asthma.ca\/get-help\/severe-asthma\/2024."},{"issue":"3","key":"10.1016\/j.anai.2025.07.005_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"issue":"12","key":"10.1016\/j.anai.2025.07.005_bib0004","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.anai.2025.07.005_bib0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jaci.2013.07.036","article-title":"Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma","volume":"133","author":"Peters","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.07.005_bib0006","first-page":"192","article-title":"A population-based study of the burden of severe asthma in Alberta, Canada","volume":"7","author":"Ramsahai","year":"2023","journal-title":"Can J Respir Crit Care Sleep Med"},{"issue":"1","key":"10.1016\/j.anai.2025.07.005_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13223-024-00891-x","article-title":"A survey of severe asthma in Canada: results from the CASCADE practice reflective program","volume":"20","author":"Godbout","year":"2024","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.anai.2025.07.005_bib0008","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Accessed June 30, 2025. Available at: www.ginasthma.com"},{"issue":"6","key":"10.1016\/j.anai.2025.07.005_bib0009","first-page":"348","article-title":"Canadian Thoracic Society 2021 guideline update: Diagnosis and management of asthma in preschoolers, children and adults","volume":"5","author":"Yang","year":"2021","journal-title":"Can J Respir Crit Care Sleep Med"},{"issue":"4","key":"10.1016\/j.anai.2025.07.005_bib0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the international severe asthma registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.anai.2025.07.005_bib0011","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2466-13-70","article-title":"Clinical, economic, and humanistic burden of asthma in Canada: a systematic review","volume":"13","author":"Ismaila","year":"2013","journal-title":"BMC Pulm Med"},{"issue":"12","key":"10.1016\/j.anai.2025.07.005_bib0012","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/thoraxjnl-2019-213223","article-title":"Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study","volume":"74","author":"Chen","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.anai.2025.07.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106670","article-title":"A systematic literature review of burden of illness in adults with uncontrolled moderate\/severe asthma","volume":"191","author":"Czira","year":"2022","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2025.07.005_bib0014","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12931-022-02266-5","article-title":"Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma","volume":"23","author":"Stubbs","year":"2022","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.anai.2025.07.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00140-2022","article-title":"SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada)","volume":"8","author":"Noorduyn","year":"2022","journal-title":"ERJ Open Res"},{"issue":"6","key":"10.1016\/j.anai.2025.07.005_bib0016","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s12325-023-02479-0","article-title":"A charter to fundamentally change the role of oral corticosteroids in the management of asthma","volume":"40","author":"Haughney","year":"2023","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.anai.2025.07.005_bib0017","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2025.07.005_bib0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.08.014","article-title":"The impact of inappropriate use of short acting beta agonists in asthma","volume":"131","author":"FitzGerald","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2025.07.005_bib0019","first-page":"19","article-title":"Relationship between short-acting \u03b22-adrenergic agonist use and healthcare costs","volume":"17","author":"Silver","year":"2011","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.anai.2025.07.005_bib0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"issue":"4","key":"10.1016\/j.anai.2025.07.005_bib0021","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00092-2019","article-title":"Prevalence of oral corticosteroid use in the German severe asthma population","volume":"5","author":"Taube","year":"2019","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.anai.2025.07.005_bib0022","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2025.07.005_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100726","article-title":"Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group","volume":"15","author":"Bleecker","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"3","key":"10.1016\/j.anai.2025.07.005_bib0024","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2025.07.005_bib0025","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s12325-024-02803-2","article-title":"Exploring perceptions of biologic therapies: A qualitative study among Canadians living with severe asthma","volume":"41","author":"Bever","year":"2024","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.anai.2025.07.005_bib0026","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle Guy","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2025.07.005_bib0027","first-page":"199","article-title":"Recognition and management of severe asthma: a Canadian Thoracic Society position statement","volume":"1","author":"FitzGerald","year":"2017","journal-title":"Can J Respir Crit Care Sleep Med"},{"key":"10.1016\/j.anai.2025.07.005_bib0028","series-title":"Regional variation in asthma prevalence and oral corticosteroid use for Canadian patients: heat map analysis","author":"Chapman","year":"2020"},{"key":"10.1016\/j.anai.2025.07.005_bib0029","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2147\/JAA.S365967","article-title":"Prevalence of patients with uncontrolled asthma despite NVL\/GINA step 4\/5 treatment in Germany","volume":"15","author":"Bergmann","year":"2022","journal-title":"J Asthma Allergy"},{"issue":"5","key":"10.1016\/j.anai.2025.07.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02391-2024","article-title":"Phenotyping the Responses to Systemic corticosteroids in the Management of Asthma Attacks (PRISMA)","volume":"65","author":"Celis-Preciado","year":"2025","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2025.07.005_bib0031","first-page":"124","article-title":"Targeted management of severe asthma: developing a Canadian approach","volume":"4","author":"Chapman","year":"2020","journal-title":"Can J Respir Crit Care Sleep Med"},{"key":"10.1016\/j.anai.2025.07.005_bib0032","unstructured":"Asthma Society of Canada. Severe asthma. Accessed March 17, 2025. Available at: https:\/\/asthma.ca\/wp-content\/uploads\/2017\/06\/SAstudy.pdf"},{"key":"10.1016\/j.anai.2025.07.005_bib0033","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13223-018-0261-x","article-title":"A multi-stakeholder perspective on asthma care in Canada: findings from a mixed methods needs assessment in the treatment and management of asthma in adults","volume":"14","author":"Murray","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.anai.2025.07.005_bib0034","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/JAA.S369836","article-title":"Management of uncontrolled asthma: a framework for novel and legacy biologic treatments","volume":"15","author":"Tan","year":"2022","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.anai.2025.07.005_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13223-023-00767-6","article-title":"Recommendations from a Canadian Delphi consensus study on best practice for optimal referral and appropriate management of severe asthma","volume":"19","author":"Godbout","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.07.005_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01872-2019","article-title":"Overuse of short-acting \u03b2(2)-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme","volume":"55","author":"Nwaru","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2025.07.005_bib0037","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41533-022-00295-7","article-title":"Short-acting \u03b22-agonist prescription patterns for asthma management in the SABINA III primary care cohort","volume":"32","author":"Price","year":"2022","journal-title":"NPJ Prim Care Respir Med"},{"issue":"1S","key":"10.1016\/j.anai.2025.07.005_bib0038","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jaip.2021.10.011","article-title":"A practical guide to implementing SMART in asthma management","volume":"10","author":"Reddel","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2025.07.005_bib0039","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2147\/JAA.S377174","article-title":"Characterization of patients in the International Severe Asthma Registry with high steroid exposure who did or did not initiate biologic therapy","volume":"15","author":"Chen","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.anai.2025.07.005_bib0040","unstructured":"Access to primary care: Many Canadians face challenges. Accessed September 9, 2024. Available at: https:\/\/www.cihi.ca\/en\/primary-and-virtual-care-access-emergency-department-visits-for-primary-care-conditions\/access-to-primary-care-many-canadians-face-challenges"},{"key":"10.1016\/j.anai.2025.07.005_bib0041","series-title":"The efficacy and safety of biologic drugs to treat severe asthma: rapid review","author":"Randall","year":"2024"},{"issue":"1","key":"10.1016\/j.anai.2025.07.005_bib0042","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12931-021-01696-x","article-title":"Trends in oral corticosteroids use in severe asthma: a 14-year population-based study","volume":"22","author":"Sadatsafavi","year":"2021","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.anai.2025.07.005_bib0043","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.anai.2025.07.005_bib0044","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1016\/j.jaip.2021.01.039","article-title":"Lower use of biologics for the treatment of asthma in publicly insured individuals","volume":"9","author":"Akenroye","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2025.07.005_bib0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.anai.2024.09.023","article-title":"Identifying super-responders: A review of the road to asthma remission","volume":"134","author":"Mailhot-Larouche","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2025.07.005_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107414","article-title":"Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient","volume":"218","author":"Rogers","year":"2023","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.anai.2025.07.005_bib0047","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"15","key":"10.1016\/j.anai.2025.07.005_bib0048","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.anai.2025.07.005_bib0049","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.anai.2022.08.637","article-title":"REAL-world effectiveness of Duplilumab on oral corticosteroid use in patients with moderate-to-severe asthma","volume":"129","author":"Pawar","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2025.07.005_bib0050","first-page":"2527","article-title":"Real-world oral glucocorticoid-sparing effect of Benralizumab in severe asthma","volume":"54","author":"Jackson","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2025.07.005_bib0051","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaip.2023.11.007","article-title":"Efficacy and safety of biologics for oral corticosteroid\u2013dependent asthma: a systematic review and network meta-analysis","volume":"12","author":"Phinyo","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2025.07.005_bib0052","article-title":"Adult asthma diagnosis: physician reported challenges in alberta-based primary care practices","volume":"6","author":"Sharpe","year":"2020","journal-title":"SAGE Open Nurs"},{"issue":"1","key":"10.1016\/j.anai.2025.07.005_bib0053","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12890-022-02295-2","article-title":"Geographical differences in the use of oral corticosteroids in patients with severe asthma in Spain: heat map based on existing databases analyses","volume":"23","author":"Almonacid","year":"2023","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.anai.2025.07.005_bib0054","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/02770903.2022.2093217","article-title":"Regional variation in prevalence of difficult-to-treat asthma and oral corticosteroid use for patients in Australia: heat map analysis","volume":"60","author":"Wark","year":"2023","journal-title":"J Asthma"},{"issue":"1","key":"10.1016\/j.anai.2025.07.005_bib0055","article-title":"Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden","volume":"9","author":"Lehtim\u00e4ki","year":"2022","journal-title":"Eur Clin Respir J"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:03:15Z","timestamp":1777608195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625003461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1081120625003461"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.07.005","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALERT (ChAracterizing uncontroLled sevERe asThma in Canada)","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}